Kornimate/medical-research-clean huggingface dataset:
the effect of pap on isshl comorbided with osa

Conditions: Sudden Hearing Loss; Obstructive Sleep Apnea

Summary: this clinical randomized controlled study is to explore the effect of positive airway pressure(pap) on patients in beijing tsinghua changgung hospital diagnosed with both idiopathic sudden sensorineural hearing loss comorbided(isshl) and obstructive sleep apnea(osa) between dec. 2019 to dec. 2029.


Eligibility criteria:
inclusion criteria: 1. aged \>= 18 and \<= 70, 2. diagnosed with osa by full-night in-lab or home-stay psg according to aasm 2012 criteria, and ahi \> 15/h, 3. diagnosed with isshl by aao-hns 2019 criteria, 4. isshl onset within 1 week. exclusion criteria: 1. sudden hearing loss with certain causes, 2. with severe comorbid diseases, 3. pregnant or breast-feeding women, 4. ahi \<= 15/h, 5. hearing threshold recovered \> 50% when included, 6. previously regularly treated with pap.
difference between mean gestational sac diameter and crown-rump length as a marker of first-trimester pregnancy outcome in patients with recurrent spontaneous abortion

Conditions: Recurrent Spontaneous Abortion

Summary: objective: to determine the effect and predictive value of the difference between the mean gestational diameter (mgsd) sac and crown-rump length (crl) of the first trimester on the pregnancy outcomes of patients with recurrent spontaneous abortion (rsa).methods: this is a retrospective cohort study. in total, 256 pregnant women at 6-10 weeks of gestation and with rsa who visited our hospital from january 2020 to march 2023 were included in the study. they were divided into the following three groups based on the difference between the mgsd and crl (mgsd-crl): group a: mgsd-crl ≥ 10mm, 41 cases; group b: 10mm \ 15mm, 106 cases.

study question: can the difference between mean gestational sac diameter and crown-rump length (mgsd-crl) act as a marker of first-trimester pregnancy outcome in patients with recurrent spontaneous abortion (rsa)? summary answer: in patients with rsa, mgsd-crl acts as an independent risk factor affecting pregnancy outcomes, as it can effectively predict the early pregnancy outcomes of patients with rsa. what is known already: rsa refers to the occurrence of two or more consecutive miscarriages with the same partner before reaching 28 weeks of gestation, which causes considerable physical and psychological distress to the patients. therefore, predicting the outcome of subsequent pregnancies in patients with rsa is important. recent studies have reported a smaller mgsd-crl difference in association with a higher rate of spontaneous abortion. in addition, thrombophilia-induced rsa has garnered increasing research attention as it is an important cause of early and late miscarriages. study design, size, duration: this is a retrospective cohort study. in total, 256 pregnant women at 6-10 weeks of gestation and with rsa who visited our hospital from january 2020 to march 2023 were included in the study. the patients were allocated to three groups based on the mgsd-crl difference: group a: mgsd-crl ≥10 mm, group b: 10 mm \ 15 mm.

Eligibility criteria:
inclusion criteria: (1) patients diagnosed with rsa based on medical history, (2) those who intend to continue the pregnancy, (3) singleton pregnancy, (4) gestational age is between 6-10 weeks, and (5) the conception for the current pregnancy was natural exclusion criteria: (1) individuals with multiple pregnancies or ectopic pregnancies, (2) conception through assisted reproductive techniques, and (3) chromosomal abnormalities in pregnant women or their partners.

Keywords: recurrent spontaneous abortion difference between mean gestational sac diameter and crown-rump length thrombophilia first-trimester pregnancy outcome
study of asoprisnil in the treatment of uterine fibroids.

Conditions: Fibroid Uterus; Leiomyoma; Menorrhagia; Metrorrhagia; Uterine Fibroids

Summary: the objective of this study is to determine the long-term safety of asoprisnil in women with abnormal uterine bleeding associated with uterine fibroids.

no medical therapy is currently available for the long-term treatment of abnormal uterine bleeding associated with uterine fibroids in women and many women must resort to surgery for relief. the objective of this study is to determine the long-term safety of two asoprisnil doses (10 and 25 mg tablets) administered daily to women who received asoprisnil in one of the asoprisnil long-term studies (study c03-062 or study m01-391). the safety endpoints for this study will include the affects of asoprisnil on the endometrium, ovaries, bone (a subset of study m01-391 subjects), lipid profiles, adverse events, and changes from baseline lab values and vital signs. some subjects receiving asoprisnil developed endometrial changes. as a result, dosing was prematurely discontinued for all subjects. to ensure safety, subjects will remain on study and will undergo scheduled study procedures. in most subjects, endometrial changes reversed after asoprisnil discontinuation.

Eligibility criteria:
inclusion criteria: * women who have completed 12 months of active treatment in study m01-391 and month 12 visit procedures or completed 18 months of active treatment in study c03-062 and month 18 visit procedures (with no more than a 14-day interruption in dosing from study c02-062 and this study) or could not continue in a previous asoprisnil study, but are now eligible for retreatment * otherwise in good health * premenopausal based on estrogen and fsh levels * adequate endometrial biopsy with no significant histological disorder * agrees to use double-barrier method of contraception exclusion criteria: * any abnormal lab or procedure result(s) the study-doctor considers important * history of a blood-clotting disorder * history of osteoporosis requiring treatment * any invasive procedure(s) (d\&c, etc) where a polyp was confirmed or a surgical or invasive procedure for uterine fibroids was performed during any previous asoprisnil study * hemoglobin \< 8.0 g/dl * endometrial thickness ≥ 19 mm

Keywords: symptomatic uterine fibroids excessive uterine bleeding uterine hemorrhage
water bolus volumes during continuous exercise in heat

Conditions: Dehydration (Physiology); Hyperthermia

Summary: hydration is important to all individuals including occupational workers who complete physical activity in the heat. current best practice guidelines suggest drinking a cup of water every 15-20 minutes during activity in a hot environment, but research shows this may not be ideal for best maintaining hydration. the goal of this study is to determine if larger, more frequent water boluses better maintain hydration than smaller, less frequent water boluses during moderate intensity physical activity in the heat.


Eligibility criteria:
inclusion criteria: * male * 18-39 y old * self-reported to be healthy exclusion criteria: * female * not within defined age range * history of any cardiovascular, neurologic, or metabolic disease * current tobacco use or regular use within the last 2 years. * taking medications with known thermoregulatory or cardiovascular effects (e.g., aspirin, beta blockers, diuretics, psychotropics, etc.) * inability to follow the rules of the protocols or understand the consent form
emergency contraception actual use study

Conditions: Emergency Contraception

Summary: this is a non-comparative case series study to assess the ability of females 11-16 years of age, inclusive, who are requesting emergency contraception (ec) to use the study product, dr-104 (plan b® 1.5), appropriately and safely without provider counseling.

to simulate an over-the-counter (otc) setting, each potential subject was expected to read the label text on the outside of the study package and determine whether and how to use the study product without provider direction or assistance. the study product, plan b® 1.5, was to be dispensed only to those subjects who appropriately self-selected and indicated that they wanted to participate in the study and receive study product. subjects could also appropriately self-select not to use the study product. follow-up contact was to be conducted at approximately one, four, and eight weeks following the date the subject was dispensed study product. at these contacts, subjects answered questions regarding product use, health problems since last contact, and pregnancy status. subjects were not to be permitted to enroll more than once in this actual use study, however to assess repeat use of emergency contraceptives (ec) (use in addition to the study product) subjects were also queried at the one-, four-, and eight-week follow-up contacts regarding use of additional ec.

Eligibility criteria:
inclusion criteria: * female and 11-16 years of age, inclusive * subject must be requesting emergency contraception for her own use (not for use by another person) and for current (not future) use * subject can read and understand english, according to her own judgment * others as dictated by fda-approved protocol
early brain damage assessment in aneurysmal subarachnoid haemorrhage in predicting cognitive impairment

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: the goal of this type of study : observation study is to learn about cerebral edema and hematoma in aneurysmal subarachnoid hemorrhage the main questions it aims to answer are current clinical practices lack predictive models to identify early structural brain abnormalities affecting cognition.

the development of a predictive model termed the a-sah early brain edema/hematoma compression neural (structural brain) networks score system (sebe-hcnnss).

Eligibility criteria:
inclusion criteria: first-ever stroke, diagnosed with sah via ct scan within 24 - 48 hours or lumbar puncture; 2) age between 18 and 70 years; 3) confirmation of cerebral aneurysm by digital subtraction angiography (dsa) and/or ct angiography (cta); 4) absence of neurological or psychiatric disease history and each unruptured intracranial aneurysm patient must be admitted to the hospital in excellent preoperative and pre-interventional condition; 5) informed consent is signed by the patient and/or family. 6)clinical diagnosis of alzheimer's disease must be able to swallow tablets. - exclusion criteria: 1) patients over 70 years old; 2) presence of neurological focal deficits or severe aphasia; 3) cognitive dysfunction or history of cognitive decline including craniotomy, antipsychotics, neurodegenerative diseases, and chronic subdural hematoma; 4) concurrent acute or chronic infections, corneal or pupillary abnormalities, severe autoimmune or systemic diseases such as rheumatic illnesses of the musculoskeletal system; 5) concurrent severe organic dysfunction; 6) patients with recurrent aneurysms or aneurysms not first diagnosed in our hospital; 7) diagnosis of major psychosis according to the diagnostic and statistical manual of mental disorders, 4th edition criteria 8)insulin dependent diabetes,9)thyroid disease
quantitative coronary angiography versus intravascular ultrasound guidance for drug-eluting stent implantation

Conditions: Coronary Disease; Coronary Stenoses

Summary: the purpose of this study is to compare clinical outcomes between quantitative coronary angiography -guided and intravascular ultrasound -guided strategy in patients with significant coronary artery disease undergoing sirolimus-eluting orsiro/orsiro mission stent implantation.


Eligibility criteria:
inclusion criteria: 1. men or women at least 19years of age 2. typical chest pain or objective evidence of myocardial ischemia suitable for elective pci 3. significant coronary artery lesions suitable for sirolimus-eluting orsiro/orsiro mission stent implantation 4. the patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethical committee of the respective clinical site. exclusion criteria: 1. angiographic exclusion criteria: any of the followings 1)bypass graft lesions 2)impaired delivery of ivus is expected: * extreme angulation (≥90°) proximal to or within the target lesion. * excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion. * heavy calcification proximal to or within the target lesion. 2. previous percutaneous coronary intervention within 6 months before the index procedure 3. previous bvs (bioresorbable vascular scaffold) implantation 4. left ventricular ejection fraction (lvef) \< 30% 5. hypersensitivity or contraindication to device material and its degradants and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated. 6. persistent thrombocytopenia (platelet count \<100,000/µl) 7. any history of hemorrhagic stroke or intracranial hemorrhage, transient ischemic attack or ischemic stroke within the past 6 months 8. a known intolerance to antiplatelet agents (aspirin, clopidogrel, prasugrel or ticagrelor) 9. any surgery requiring general anesthesia or discontinuation of aspirin and/or an adp antagonist is planned within 12 months after the procedure. 10. a diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer. 11. any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study. 12. hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (alt or ast \> 3 times upper limit of normal). 13. life expectancy \< 1 years for any non-cardiac or cardiac causes 14. unwillingness or inability to comply with the procedures described in this protocol. 15. patient's pregnant or breast-feeding or child-bearing potential.

Keywords: ivus guided pci qca guided pci
ovemp in myasthenia

Conditions: Myasthenia Gravis, Ocular

Summary: myasthenia gravis is an autoimmune disorder of neuromuscular transmission, characterized by fluctuating muscle weakness and fatigability. in isolated ocular myasthenia, when only the extraocular muscles are involved, most common ancillary tests, such as acetylcholine receptor autoantibodies and repetitive nerve stimulation, are often negative. a simple, quick and non-invasive test for ocular myasthenia based on ocular vestibular evoked myogenic potentials (ovemp) was recently developed. the main goal of the study is to validate repetitive ovemp stimulation in a blinded diagnostic accuracy study in order to facilitate early and accurate diagnosis of ocular myasthenia.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * patients with diplopia and/or ptosis suspicious for myasthenia gravis. exclusion criteria: * vestibular disorders * significant systemic myasthenia symptoms (respiration or swallowing difficulties) unable to undergo ovemp testing. * patients with significant cardiac or respiratory disease will be excluded from the tensilon test as part of the reference standard. * women who are pregnant or breast feeding.

Keywords: ocular vestibular evoked myogenic potentials
group psychotherapy in narcolepsy type 1

Conditions: Narcolepsy Type 1

Summary: the aim of this pilot study is to test the benefit of behavior therapy-oriented, method-integrated psychotherapy in an outpatient group setting in patients with narcolepsy type 1. therefore we collect and evaluate initial data on its effectiveness on the disease in terms of specific symptomatology, emotion regulation, health-related quality of life, and disease processing/acceptance.


Eligibility criteria:
inclusion criteria: * diagnosed narcolepsy type 1 according to aasm, examined by an experienced sleep physician including history, clinical examination, polysomnographic examination (psg) with a multiple sleep latency test (mslt), possibly also including determination of hla dqb1 \* 062 and orexin a / hypocretin 1 * age between 18 and 65 years * signed informed consent * exclusion of other clinically relevant organic sleep disorders by means of polysomnography (ahi\>10/h) exclusion criteria: * presence of severe psychiatric comorbidity * other psychotherapy during the study period * change of medication used for narcolepsy therapy shortly before the start and during the study period including follow-up measurement. in this case, patients may still complete group therapy, but the data will not be included in the analysis.

Keywords: narcolepsy type 1 narcolepsy narcolepsy with cataplexy group psychotherapy group therapy psychotherapy
neural bases of cognitive rehabilitation for brain injury

Conditions: Brain Injury

Summary: some of the most common and disabling consequences of brain injury are deficits in cognition, such as difficulty with sustained attention, memory, organization, and goal management. the long-term goal of this research program is to develop and test novel neuroscience-based cognitive interventions for improving attentional regulation and related "executive function" brain processes involved in goal-directed behavior.

brain injury often results in a disruption of attention regulation processes, which reduces the efficiency and effectiveness of cognitive functions including learning, memory, problem-solving and goal management, leading to significant functional disability. more intervention options are needed. we set out to test different possible interventions. individuals with traumatic brain injury (tbi) and chronic executive control dysfunction participate in interventions, with pre- and post-intervention measurements of cognitive functioning. training in goal-oriented attentional self-regulation (goals) was administered in comparison to brain health education (edu). goals is designed to train attention regulation skills along with meta-cognitive strategies for goal management, with a emphasis on application to participant-selected projects. this is a group-based intervention. brain health education is designed to increase knowledge and understanding of key factors that affect brain functioning. this is a group-based intervention matched to the goals intervention.

Eligibility criteria:
inclusion criteria: patients with a history of tbi (reported plausible mechanism of head injury, loss of consciousness with some period of post-traumatic alteration in cognition) who are \> 6 months post-injury will be screened for evidence of mild-moderate residual dysfunction in executive control functions based on corroborated reports of real-world difficulties (mayo-portland adaptability inventory). exclusion criteria: * severely apathetic/abulic * aphasic * or other reasons for patients being unable or unwilling to participate with the training tasks * severe cognitive dysfunction * history of neurodevelopmental abnormalities * ongoing illicit drug or alcohol abuse (audit\>8) * severe depression as measured by beck depression inventory (\>29) * severe ptsd precluding participation in research activities (such as group training or mri scanning) * there will be no restriction in regard to gender, race and socioeconomic status.

Keywords: executive dysfunction brain injury attention rehabilitation
the effect of low back pain on paraspinal muscles

Conditions: Low Back Pain

Summary: low back pain is frequently seen in the adolescent age group, with a prevalence approaching that of the adult age group. the most common type is non-specific, self-limiting low back pain. ldh is rare in children and adolescents and generally presents with low back pain, with or without radiculopathy. the condition is usually unilateral (especially l4-5 or l5-s1). ldh is also mostly central type. although there are many studies that have investigated the relationship between paraspinal muscle volumes and lbp and/or ldh in the adult age group, there are very few studies in adolescents. the principal aim of this study was to compare mf, es, and pm volumes in adolescents with lbp with and without ldh using magnetic resonance imaging (mri) and to determine whether these two conditions cause paraspinal muscle volume loss.

the medical records of 229 patients who underwent mri due to low back pain persisting for a minimum of twelve weeks between january 2018 and january 2020 were evaluated retrospectively. twenty-four patients were excluded due to the presence of spondylolysis-listhesis, spinal alignment disorders including scoliosis and kyphosis, inflammatory diseases, or histories of spinal surgery and multilevel disc hernia. two hundred five patients were finally enrolled. age, gender, weight, and height were recorded, and bmi was calculated as weight/(height)². participants were divided into two groups - with ldh (group a) and without ldh (group b). right- and left-side ps, mf, and es muscle volumes at intervertebral disc levels l4-l5 and l5-s1 were measured on axial t2-weighted fast spin-echo sequences. all cross-sectional images at both levels (l4-5 and l5-s1) were generated by means of multiplanar reformat images. the muscles were identified by means of manual contouring at both disc levels. the fat components were then eliminated by application of the threshold technique, based on visual differences in pixel signal intensities. volume measurement from cross-sectional images was based on the use of an automatic volume calculation tool.

Eligibility criteria:
inclusion criteria: * aged 10-18 * lbp persisting for a minimum of twelve weeks exclusion criteria: * spondylolysis-listhesis * spinal alignment disorders including scoliosis and kyphosis * inflammatory diseases * histories of spinal surgery * multilevel disc hernia

Keywords: adolescent low back pain lumbar disc herniation paraspinal muscle magnetic resonance imaging
long-term ol study of [s,s]-rbx in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: to evaluate the lon-term safety and tolerability of \[s,s\]-reboxetine in patients with fibromyalgia


Eligibility criteria:
inclusion criteria: * diagnosis of patients meeting the acr criteria for fibromyalgia (i.e. widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites) exclusion criteria: * patients with other severe pain (e.g. dpn and phn) that may confound assessment or self-evaluation of the pain associated with fibromyalgia